Journal Home > Volume 1 , Issue 2
Cancer Innovation 2022, 1(2): 119-123 https://doi.org/10.1002/cai2.21
Commentary | Open Access | Issue | Published: 14 July 2022

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer

Show Author's Information Xiuwen Guan1,  Fei Ma1,2 ( ),  Binghe Xu1,2( )
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Keywords:
breast cancer, tyrosine kinase inhibitor, HER2‐targeted therapy
Cite this article:
Guan X, Ma F, Xu B. Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer. Cancer Innovation, 2022, 1(2): 119-123. https://doi.org/10.1002/cai2.21
Download citation
EndNote(RIS)
BibTeX

791

Views

50

Downloads

Citations

5

Crossref

N/A

WoS

5

Scopus

N/A

CSCD

Abstract Full text About this article

menu
Abstract
Full text
Outline
About this article

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer

Show Author's information Xiuwen Guan1, Fei Ma1,2 ( ), Binghe Xu1,2( )
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Keywords: breast cancer, tyrosine kinase inhibitor, HER2‐targeted therapy

References(10)

Loibl S, Gianni L. HER2‐positive breast cancer. Lancet. 2017;389(10087):2415–29.
DOI Google Scholar
Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, et al. Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142‐56.
DOI Google Scholar
Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, et al. Pyrotinib or lapatinib combined with capecitabine in HER2‐positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study. J Clin Oncol. 2019;37(29):2610‐19.
DOI Google Scholar
Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2‐positive metastatic breast cancer (PHOEBE): a multicentre, open‐label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351‐60.
DOI Google Scholar
Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: a randomized phase III study. J Clin Oncol. 2019;37(Suppl 15):1001–2619.
DOI Google Scholar
Shiraishi K, Mimura K, Izawa S, Inoue A, Shiba S, Maruyama T, et al. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab‐mediated antibody‐dependent cellular cytotoxicity. Gastric Cancer. 2013;16(4):571–80.
DOI Google Scholar
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2‐positive early breast cancer (NeoALTTO): a randomised, open‐label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40.
DOI Google Scholar
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2‐positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.
DOI Google Scholar
US National Library of Medicine. ClinicalTrials.gov [online]. https://www.clinicaltrials.gov/ct2/show/NCT03863223?term=NCT03863223%26rank=1. Accessed 3 Jan 2022.
DOI
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2‐positive metastatic breast cancer (CLEOPATRA): end‐of‐study results from a double‐blind, randomised, placebo‐controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 26 February 2022
Accepted: 06 June 2022
Published: 14 July 2022
Issue date: August 2022

Copyright

© 2022 The Authors.

Acknowledgements

We thank all the directors and study coordinators for presenting the referred clinical trials.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

Return